{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-079454","form_type":"8-K","ticker":"TRAW","cik":"0001130598","company_name":"Traws Pharma, Inc.","filed_at":"2025-08-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.411966+00:00","generated_at":"2026-05-17T11:48:17.859468+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Traws Pharma gets HREC approval for Phase 2 COVID trials of ratutrelvir; top-line data expected year-end 2025","bullets":["First Phase 2 non-inferiority trial compares ratutrelvir 600 mg QD for 10 days vs PAXLOVID 5-day regimen in newly diagnosed COVID subjects.","Second single-arm trial tests ratutrelvir in PAXLOVID-ineligible patients; both trials expect top-line results by year-end 2025.","Ratutrelvir is ritonavir-free, once-daily for 10 days, aiming to reduce clinical rebound and Long COVID risk.","Pfizer reported $427M PAXLOVID sales in Q2 2025 (+70% YoY), highlighting continued market need for COVID treatments."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-079454","json":"https://secwatch.observer/filing/0001104659-25-079454.json","markdown":"https://secwatch.observer/filing/0001104659-25-079454.md","text":"https://secwatch.observer/filing/0001104659-25-079454.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925079454/0001104659-25-079454-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925079454/tm2523715d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T11:48:17.859468+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}